Clinical Trials for Gracell Biotechnologies

Explore 8 clinical trials worldwide

Showing 1-8 of 8 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Gracell Biotechnologies

Clinical Trials (8)

NCT07086404
GC012F Injection in Refractory Idiopathic Inflammatory Myopathy
EARLY_PHASE1Not yet recruiting
12 participants
Started: Sep 15, 2025 · Completed: Sep 15, 2029
1 condition3 sponsors0 locations
NCT07072884
GC012F in Patients With Autoimmune Diseases
EARLY_PHASE1Not yet recruiting
15 participants
Started: Aug 18, 2025 · Completed: Mar 31, 2029
2 conditions2 sponsors0 locations
NCT07058298
GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)
EARLY_PHASE1Recruiting
6 participants
Started: Jul 15, 2025 · Completed: Sep 10, 2027
1 condition2 sponsors1 location
NCT06235229
A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma
PHASE1/PHASE2Recruiting
110 participants
Started: Jun 18, 2025 · Completed: Mar 2, 2026
1 condition1 sponsor10 locations
NCT06880354
A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
PHASE1Recruiting
37 participants
Started: May 22, 2025 · Completed: Mar 31, 2028
1 condition3 sponsors1 location
NCT06759948
An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis
PHASE1Not yet recruiting
18 participants
Started: Feb 15, 2025 · Completed: Sep 10, 2027
1 condition2 sponsors1 location
NCT06530849
A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus
PHASE1/PHASE2Recruiting
118 participants
Started: Aug 22, 2024 · Completed: Feb 1, 2027
1 condition3 sponsors2 locations
NCT05840107
Study of FasT CAR-T GC012F Injection NDMM Patients
EARLY_PHASE1Recruiting
18 participants
Started: May 4, 2023 · Completed: Sep 30, 2025
1 condition2 sponsors1 location